OncoCyte Corp (NYSEMKT:OCX) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Thursday.
OncoCyte Corp (NYSEMKT OCX) opened at 6.10 on Thursday. OncoCyte Corp has a 1-year low of $3.75 and a 1-year high of $7.95. The company’s market cap is $191.15 million. The firm’s 50-day moving average is $6.59 and its 200 day moving average is $6.59.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Equities Focus and is owned by of Equities Focus. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.equitiesfocus.com/2017/10/05/valuengine-lowers-oncocyte-corp-ocx-to-sell.html.
OncoCyte Corp Company Profile
OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.
Receive News & Ratings for OncoCyte Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte Corp and related companies with MarketBeat.com's FREE daily email newsletter.